Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

This study has been completed.
Sponsor:
Information provided by:
Walter Reed Army Medical Center
ClinicalTrials.gov Identifier:
NCT00413751
First received: December 19, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
  Purpose

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.


Condition Intervention
Healthy
Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Study Type: Observational
Study Design: Time Perspective: Longitudinal

Resource links provided by NLM:


Further study details as provided by Walter Reed Army Medical Center:

Estimated Enrollment: 20
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

  • Patients not meeting above stated age criteria
  • Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
  • History of serious ocular, neurological, cardiovascular disease
  • History of severe systemic disease
  • History of arrhythmias or high blood pressure
  • Patients currently taking any type of ocular or systemic medications except multivitamins.
  • Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413751

Locations
United States, District of Columbia
Walter Reed Army Medical Center
Washington, District of Columbia, United States, 20307
Sponsors and Collaborators
Walter Reed Army Medical Center
Investigators
Principal Investigator: KRAIG S. BOWER, MD Walter Reed Army Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00413751     History of Changes
Other Study ID Numbers: WRAMC WU #03-23004
Study First Received: December 19, 2006
Last Updated: December 19, 2006
Health Authority: United States: Federal Government

Keywords provided by Walter Reed Army Medical Center:
Large pupils rendering night vision difficulties such as haloes, glare, and monocular diplopia

Additional relevant MeSH terms:
Ophthalmic Solutions
Pharmaceutical Solutions
Brimonidine
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 15, 2014